BIO-Europe® 2016: Freshly-appointed Auspherix CEO highlights new antibiotic class

November 22, 2016
Dr. Neil Miller, the recently-appointed CEO of UK-based biotech, Auspherix, talks to Scrip about the company's new class of antibiotics and how it hopes to address the worldwide antimicrobial resistance crisis. Miller chats to Scrip senior writer, Lucie Ellis, about the science behind Auspherix's gram-negative targeting new antibiotic class and the development timeline for the company's preclinical assets. Miller was previously CSO of Auspherix, which is developing a novel class of organogold antibacterials. In parallel to Miller's promotion, Auspherix has appointed Dr. Richard Rutter CSO and Dr. Paul King head of chemistry.
Previous Video
BIO-Europe® 2016: F-star business chief discuss Denali deal and potential F-star delta spinout
BIO-Europe® 2016: F-star business chief discuss Denali deal and potential F-star delta spinout

Jane Dancer, chief business officer at F-star—a Cambridge, UK-based biotech—chats with Mike Ward, global di...

Next Video
BIO-Europe® 2016: Cinfa outlines biosimilar development areas and deal opportunities
BIO-Europe® 2016: Cinfa outlines biosimilar development areas and deal opportunities

Cinfa Biotech's managing director, Ruediger Jankowsky, chats with Mike Ward, global director of content for...